SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo

International Immunopharmacology

Volumn 9, Issue 13-14, 2009, Pages 1509-1517

  Hou, Li Fei ^a   He, Shi Jun ^a   Wang, Jun Xia ^a   Yang, Yang ^b   Zhu, Feng Hua ^a   Zhou, Yu ^a   He, Pei Lan ^a   Zhang, Yu ^a   Yang, Yi Fu ^b   Li, Ying ^a   Tang, Wei ^a   Zuo, Jian Ping ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Akt; Apoptosis; Artemisinin; Delayed type hypersensitivity; IL 2; SM934; T lymphocytes; TCR

Indexed keywords

ARTEMISININ DERIVATIVE; BETA AMINOARTEETHER MALEIC ACID; CD3 ANTIBODY; CD69 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; OVALBUMIN; PROTEIN KINASE B; SM 934; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; ENZYME PHOSPHORYLATION; FEMALE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MITOSIS INHIBITION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHEEP ERYTHROCYTE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APOPTOSIS; ARTEMISININS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; PROTO-ONCOGENE PROTEINS C-AKT; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 70350572355     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.09.003     Document Type: Article

References (33)

1. White N.J. Qinghaosu (artemisinin): the price of success. Science 320 (2008) 330-334
2. Chen H., and Maibach H.I. Topical application of artesunate on guinea pig allergic contact dermatitis. Contact Dermatitis 30 (1994) 280-282
3. Yu Q., and Gao Y. Systemic lupus erythematosus treated with artesunate. Zhongguo Pi Fu Xing Bing Xue Za Zhi 30 (1997) 51-52
4. Lu L. Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis. Zhongguo Zhongxiyi Jiehe Zazhi 22 (2002) 169-171
5. Yang Z.S., Wang J.X., Zhou Y., Zuo J.P., and Li Y. Synthesis and immunosuppressive activity of new artemisinin derivatives. Part 2: 2-[12(beta or alpha)-dihydroartemisinoxymethyl (or 1′-ethyl)]phenoxyl propionic acids and esters. Bioorg Med Chem 14 (2006) 8043-8049
6. Yang Z.S., Zhou W.L., Sui Y., Wang J.X., Wu J.M., et al. Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-dihydroartemisininoxy] phen(ox)yl aliphatic acids and esters. J Med Chem 48 (2005) 4608-4617
7. Samelson L.E., Donovan J.A., Isakov N., Ota Y., and Wange R.L. Signal transduction mediated by the T-cell antigen receptor. Ann N Y Acad Sci 766 (1995) 157-172
8. Akbar A.N., Borthwick N., Salmon M., Gombert W., Bofill M., et al. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med 178 (1993) 427-438
9. Orteu C.H., Poulter L.W., Rustin M.H., Sabin C.A., Salmon M., and Akbar A.N. The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. J Immunol 161 (1998) 1619-1629
10. Rieux-Laucat F., Le Deist F., and Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 10 (2003) 124-133
11. Mountz J.D., Wu J., Cheng J., and Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 37 (1994) 1415-1420
12. Bierer B.E., Holländer G., Fruman D., and Burakoff S.J. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 5 (1993) 763-773
13. Fontenot J.D., Rasmussen J.P., Gavin M.A., and Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6 (2005) 1142-1151
14. Nelson B.H. IL-2, regulatory T cells, and tolerance. J Immunol 172 (2004) 3983-3988
15. Kammer G.M. Altered regulation of IL-2 production in systemic lupus erythematosus: an evolving paradigm. J Clin Invest 115 (2005) 836-840
16. Gutierrez-Ramos J.C., Andreu J.L., Revilla Y., Viñuela E., and Martinez C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 346 (1990) 271-274
17. Yang Y.F., Mukai T., Gao P., Yamaguchi N., Ono S., et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 32 (2002) 2124-2132
18. Liu K., and Xu Q. Roxithromycin inhibits the effector phase of delayed-type hypersensitivity. Int Immunopharmacol 8 (2008) 126-131
19. Gonzalez J., Harris T., Childs G., and Prystowsky M.B. Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Blood Cells Mol Dis 27 (2001) 572-585
20. Zhou W.L., Wu J.M., Wu Q.L., Wang J.X., Zhou Y., et al. A novel artemisinin derivative, 3-(12-beta-artemisininoxy) phenoxyl succinic acid (SM735), mediates immunosuppressive effects in vitro and in vivo. Acta Pharmacol Sin 26 (2005) 1352-1358
21. Wang J.X., Tang W., Shi L.P., Wan J., Zhou R., et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol 150 (2007) 652-661
22. Wang J.X., Tang W., Yang Z.S., Wan J., Shi L.P., et al. Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo. Eur J Pharmacol 564 (2007) 211-218
23. Veerasubramanian P., Gosi P., Limsomwong C., and Walsh D.S. Artesunate and a major metabolite, dihydroartemisinin, diminish mitogen-induced lymphocyte proliferation and activation. Southeast Asian J Trop Med Public Health 37 (2006) 838-847
24. Yang S.X., Xie S.S., Gao H.L., and Long Z.Z. Artemisinin and its derivatives enhance T lymphocyte-mediated immune responses in normal mice and accelerate immunoreconstitution of mice with syngeneic bone marrow transplantation. Clin Immunol Immunopathol 69 (1993) 143-148
25. Kelly E., Won A., Refaeli Y., and Van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol 168 (2002) 597-603
26. Thèze J., Alzari P.M., and Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 17 (1996) 481-486
27. Kirken R.A., Rui H., Malabarba M.G., Howard O.M., Kawamura M., et al. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. Cytokine 7 (1995) 689-700
28. Winston L.A., and Hunter T. Intracellular signalling: putting JAKs on the kinase MAP. Curr Biol 6 (1996) 668-671
29. Ravichandran K.S., Igras V., Shoelson S.E., Fesik S.W., and Burakoff S.J. Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling. Proc Natl Acad Sci U S A 93 (1996) 5275-5280
30. Van Parijs L., Refaeli Y., Lord J.D., Nelson B.H., Abbas A.K., and Baltimore D. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11 (1999) 281-288
31. Ahmed N.N., Grimes H.L., Bellacosa A., Chan T.O., and Tsichlis P.N. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A 94 (1997) 3627-3632
32. Brennan P., Babbage J.W., Burgering B.M., Groner B., Reif K., and Cantrell D.A. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7 (1997) 679-689
33. Breslin E.M., White P.C., Shore A.M., Clement M., and Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 144 (2005) 791-800